A Phase 1/1b, Open-Label, Multicentre, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
This is a phase 1/1b open-label, multicentre, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumour activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumours. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumour activity of T cells and other immune cells.
Primary Outcome:
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the Canadian Cancer Society